Novartis reveals cancer cases possibly linked to gene therapy Zolgensma

AI Summary

Novartis reported cancer cases in nine people who received its gene therapy Zolgensma, including two cases with evidence that the viral delivery tool integrated into patient DNA. The findings could prompt further questions about the safety of gene therapies and their delivery mechanisms.

The occurrence of cancer in nine recipients — two of which involved evidence that a viral delivery tool integrated into patient DNA — could raise new questions for the gene therapy field.